Novartis/GSK Cancer Deal Gets FTC OK Based On Existing Divestments

Novartis’ transfer of Phase III BRAF and MEK inhibitors to partner Array BioPharma satisfies Federal Trade Commission’s anticompetitive concerns; no divestiture yet announced for GSK acquisition of Novartis [W#201420152]vaccines.